On March 26, 2025 SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, reported it will present new data from two of its antibody-drug conjugate (ADC) programs for the treatment of solid tumors, showcasing advancements in its innovative pipeline (Press release, SOTIO, MAR 26, 2025, View Source [SID1234651497]). The presentations will take place at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting in Chicago, IL from April 25-30, 2025.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

SOT106 is being developed for the treatment of patients with sarcomas and other LRRC15-positive tumors. The oral presentation at AACR (Free AACR Whitepaper) will feature new preclinical in vitro and in vivo data. SOT106 targets leucine-rich repeat containing protein 15 (LRRC15), a protein that is commonly overexpressed in mesenchymal malignancies.

SOT109 is being developed for the treatment of colorectal cancer and other gastrointestinal cancers. It targets cadherin-17 (CDH17), a protein homogenously overexpressed in more than 90% of colorectal cancers. The poster presentation at AACR (Free AACR Whitepaper) will showcase preclinical data on the efficacy and safety of SOT109 across various models.

Presentation details are as follows:

Oral Presentation Title: "SOT106, a novel best-in-class antibody-drug conjugate targeting LRRC15, to treat sarcomas and other advanced solid cancers"
Abstract Number: 1164
Session: Experimental and Molecular Therapeutics / Antibody-Based Cancer Therapeutic Agents
Presenting Author: Michaela Fojtu
Date & Time: April 27, 2025, 3:00 p.m. – 5:00 p.m. CT

Poster Title: "Preclinical safety and efficacy of SOT109, an antibody-drug conjugate targeting Cadherin 17 (CDH17) for the treatment of colorectal and other gastrointestinal tract tumors"
Abstract Number: 5469
Session: Experimental and Molecular Therapeutics
Presenting Author: Nataliia Kalynovska
Date & Time: April 29, 2025, 2:00 p.m. – 5:00 p.m. CT
Location: Poster Section 15, Board Number 27

Presentation materials will be made available here after presentations at AACR (Free AACR Whitepaper) conclude.